BACKGROUND: To evaluate the activity and toxicity of docetaxel in patients with metastatic esophageal cancer. PATIENTS AND METHODS: Eligible patients had histologically confirmed carcinoma of the esophagus with measurable metastatic sites according to Response Evaluation Criteria in Solid Tumors (RECIST). Patients were either chemotherapy-naïve or previously treated with one regimen of chemotherapy. Docetaxel 70 mg/m(2) was administered intravenously over 1-2 h, every 21 days. RESULTS: Of 52 patients enrolled in this study, three were excluded because they did not receive docetaxel due to worsening condition after enrollment. Thirty-six patients had received prior platinum-based chemotherapy. The majority of patients (94%) had squamous cell carcinoma. Ten of 49 evaluable patients [20%; 95% confidence interval (CI) 10-34%] showed a partial response. Of the 10 partial responses, six patients had received prior platinum-based chemotherapy. Grade 3 or 4 neutropenia was noted in 43 of 49 patients (88%), and nine of 49 patients (18%) developed febrile neutropenia. Twenty-eight of 49 patients (57%) required lenograstim. Grade 3 anorexia and fatigue occurred in nine (18%) and six (12%) patients, respectively. Median survival time was 8.1 months (95% CI 6.6-11.3) and the 1-year survival rate was 35% (95% CI 21-48%). CONCLUSIONS: Docetaxel as a single agent is effective in esophageal cancer, but careful management of neutropenia is needed.
BACKGROUND: To evaluate the activity and toxicity of docetaxel in patients with metastatic esophageal cancer. PATIENTS AND METHODS: Eligible patients had histologically confirmed carcinoma of the esophagus with measurable metastatic sites according to Response Evaluation Criteria in Solid Tumors (RECIST). Patients were either chemotherapy-naïve or previously treated with one regimen of chemotherapy. Docetaxel 70 mg/m(2) was administered intravenously over 1-2 h, every 21 days. RESULTS: Of 52 patients enrolled in this study, three were excluded because they did not receive docetaxel due to worsening condition after enrollment. Thirty-six patients had received prior platinum-based chemotherapy. The majority of patients (94%) had squamous cell carcinoma. Ten of 49 evaluable patients [20%; 95% confidence interval (CI) 10-34%] showed a partial response. Of the 10 partial responses, six patients had received prior platinum-based chemotherapy. Grade 3 or 4 neutropenia was noted in 43 of 49 patients (88%), and nine of 49 patients (18%) developed febrile neutropenia. Twenty-eight of 49 patients (57%) required lenograstim. Grade 3 anorexia and fatigue occurred in nine (18%) and six (12%) patients, respectively. Median survival time was 8.1 months (95% CI 6.6-11.3) and the 1-year survival rate was 35% (95% CI 21-48%). CONCLUSIONS:Docetaxel as a single agent is effective in esophageal cancer, but careful management of neutropenia is needed.
Authors: In Keun Choi; Hee Yun Seo; Hwa Jung Sung; Kyong Hwa Park; Seok Jin Kim; Sang Cheul Oh; Jae Hong Seo; Chul Won Choi; Byung Soo Kim; Sang Won Shin; Yeul Hong Kim; Jun Suk Kim Journal: Med Oncol Date: 2007 Impact factor: 3.064
Authors: Maria Alsina; Fernando Rivera; Francisco Javier Ramos; Maica Galán; Rafael López; Pilar García-Alfonso; José Enrique Alés-Martinez; Bernardo Queralt; Antonio Antón; Alfredo Carrato; Cristina Grávalos; Maria José Méndez-Vidal; Carlos López; Inmaculada Ruiz de Mena; Josep Tabernero; Jordi Giralt; Enrique Aranda Journal: Target Oncol Date: 2018-02 Impact factor: 4.493
Authors: Min-Young Lee; Ki Sun Jung; Hae Su Kim; Ji Yun Lee; Sung Hee Lim; Moonjin Kim; Hyun Ae Jung; Sung Min Kim; Jong Mu Sun; Myung-Ju Ahn; Jeeyun Lee; Se Hoon Park; Seong Yoon Yi; In Gyu Hwang; Sang-Cheol Lee; Hee Kyung Ahn; Do Hyoung Lim; Soon Il Lee; Keon Woo Park Journal: World J Gastroenterol Date: 2015-04-14 Impact factor: 5.742
Authors: Nicholas W Choong; Ann M Mauer; Daniel C Haraf; Mark K Ferguson; Alan B Sandler; Kenneth A Kesler; Paul A S Fishkin; Rafat H Ansari; James Wade; Stuart A Krauss; David F Sciortino; Mitchell C Posner; Masha Kocherginsky; Philip C Hoffman; Livia Szeto; Everett E Vokes Journal: Med Oncol Date: 2010-08-21 Impact factor: 3.064